FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer
The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda to treat locally advanced or metastatic urothelial cancer.
The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda to treat locally advanced or metastatic urothelial cancer.
What's Your Reaction?
